

Global Myasthenia Gravis Treatment Market Size study, by Treatment Type (Thymectomy, Cholinesterase Inhibitors, Rapid Immunotherapies), by End-use (Hospitals, Clinics), and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G68168029DA5EN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,750.00 (Single User License)

ID: G68168029DA5EN

Abstracts

The Global Myasthenia Gravis Treatment Market is valued at approximately USD 2.19 billion in 2023 and is anticipated to grow with a healthy CAGR of more than 9.00% over the forecast period 2024-2032. Myasthenia Gravis, a chronic autoimmune neuromuscular disorder, disrupts communication between nerves and muscles, resulting in fluctuating muscle weakness. The increasing prevalence of autoimmune diseases, combined with the rising global awareness and advances in neurology and immunotherapy, has led to a surge in demand for effective treatments. From surgical interventions like thymectomy to pharmacological options such as cholinesterase inhibitors and cutting-edge rapid immunotherapies, the therapeutic landscape is undergoing transformational progress. With healthcare systems striving to personalize treatment regimens and minimize side effects, the market is poised for a significant evolution through tailored therapies and robust pipeline innovations.

Driving this momentum are the expanding clinical trials, public-private partnerships, and aggressive investments in neurodegenerative disease research. The biopharmaceutical sector is channeling resources into developing targeted therapies with superior efficacy profiles and minimal immunogenicity. Additionally, governmental health initiatives focused on rare and chronic illnesses are incentivizing innovation and accelerating the market's commercial trajectory. For example, strategic funding from health ministries and global health organizations is enabling research into monoclonal antibodies and complement inhibitors that demonstrate promising results in reducing disease severity. However, despite these advancements, the high cost of biologics, limited patient

awareness in low-income regions, and the diagnostic complexity of Myasthenia Gravis continue to pose significant barriers to widespread treatment adoption.

Market competitiveness is further intensified by increasing collaboration between pharma giants and research institutions to leverage advanced diagnostic tools and biologics manufacturing technologies. As precision medicine gains traction, stakeholders are leaning into genomic insights and biomarker-led strategies to craft next-generation therapeutics. Simultaneously, the integration of AI-driven diagnostic platforms in healthcare infrastructures is facilitating early detection and tailored intervention strategies. The convergence of data science with neuroimmunology not only optimizes resource allocation but also sharpens drug development pipelines, ensuring quicker time-to-market for novel treatments. In parallel, regulatory bodies are offering fast-track designations and orphan drug statuses to hasten drug approvals, thereby catalyzing growth across therapeutic verticals.

Geographically, North America remains at the forefront of the Myasthenia Gravis Treatment Market, underpinned by a robust healthcare ecosystem, high disease awareness, and substantial R&D investment. The presence of leading biopharmaceutical companies and the rapid adoption of innovative therapeutics reinforce its dominant stance. Europe closely follows, driven by strategic healthcare reforms and increased focus on rare disease management through public healthcare programs. Meanwhile, Asia Pacific is projected to witness the fastest growth over the forecast period. Countries such as China, Japan, and India are demonstrating increased healthcare spending, growing medical infrastructure, and rising awareness initiatives, all contributing to an expanding patient pool and escalating treatment demand across the region.

Major market player included in this report are:

Alexion Pharmaceuticals, Inc.

F. Hoffmann-La Roche Ltd.

Novartis AG

GlaxoSmithKline plc

Pfizer Inc.

AbbVie Inc.

CSL Behring

Grifols, S.A.

argenx SE

Bausch Health Companies Inc.

Catalyst Pharmaceuticals

Takeda Pharmaceutical Company Limited

Immunovant, Inc.

CuraTeQ Biologics

UCB S.A.

The detailed segments and sub-segment of the market are explained below:

By Treatment Type

Thymectomy

Cholinesterase Inhibitors

Rapid Immunotherapies

By End-use

Hospitals

Clinics

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Contents

CHAPTER 1. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET EXECUTIVE SUMMARY

- 1.1. Global Myasthenia Gravis Treatment Market Size & Forecast (2022 – 2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Treatment Type
 - 1.3.2. By End-use
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Consumer's Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory Frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Environmental Considerations
 - 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET DYNAMICS

3.1. Market Drivers

- 3.1.1. Rising Prevalence of Autoimmune Neuromuscular Disorders
- 3.1.2. Advancements in Immunotherapy and Precision Medicine
- 3.1.3. Escalating R&D Investments and Public-Private Collaborations

3.2. Market Challenges

- 3.2.1. High Cost of Biologics and Treatment Regimens
- 3.2.2. Diagnostic Complexity and Delayed Detection
- 3.2.3. Limited Awareness in Emerging Economies

3.3. Market Opportunities

- 3.3.1. Expansion in Asia Pacific and Latin America
- 3.3.2. Integration of AI-Driven Diagnostic Platforms
- 3.3.3. Development of Novel Rapid Immunotherapies

CHAPTER 4. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET INDUSTRY ANALYSIS

4.1. Porter's 5 Force Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunity

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspective

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE & FORECASTS BY TREATMENT TYPE 2022 – 2032

5.1. Segment Dashboard

5.2. Global Myasthenia Gravis Treatment Market: Treatment Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)

5.2.1. Thymectomy

5.2.2. Cholinesterase Inhibitors

5.2.3. Rapid Immunotherapies

CHAPTER 6. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE & FORECASTS BY END-USE 2022 – 2032

6.1. Segment Dashboard

6.2. Global Myasthenia Gravis Treatment Market: End-use Revenue Trend Analysis, 2022 & 2032 (USD Billion)

6.2.1. Hospitals

6.2.2. Clinics

CHAPTER 7. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE & FORECASTS BY REGION 2022 – 2032

7.1. North America Market

7.1.1. U.S. Market

7.1.1.1. Treatment Type Breakdown Size & Forecasts, 2022 – 2032

7.1.1.2. End-use Breakdown Size & Forecasts, 2022 – 2032

7.1.2. Canada Market

7.2. Europe Market

7.2.1. UK Market

7.2.2. Germany Market

7.2.3. France Market

7.2.4. Spain Market

7.2.5. Italy Market

7.2.6. Rest of Europe Market

7.3. Asia Pacific Market

7.3.1. China Market

7.3.2. India Market

7.3.3. Japan Market

7.3.4. Australia Market

7.3.5. South Korea Market

7.3.6. Rest of Asia Pacific Market

- 7.4. Latin America Market
 - 7.4.1. Brazil Market
 - 7.4.2. Mexico Market
 - 7.4.3. Rest of Latin America Market
- 7.5. Middle East & Africa Market
 - 7.5.1. Saudi Arabia Market
 - 7.5.2. South Africa Market
 - 7.5.3. Rest of Middle East & Africa Market

CHAPTER 8. COMPETITIVE INTELLIGENCE

- 8.1. Key Company SWOT Analysis
 - 8.1.1. Alexion Pharmaceuticals, Inc.
 - 8.1.2. F. Hoffmann-La Roche Ltd.
 - 8.1.3. Novartis AG
- 8.2. Top Market Strategies
- 8.3. Company Profiles
 - 8.3.1. Alexion Pharmaceuticals, Inc.
 - 8.3.1.1. Key Information
 - 8.3.1.2. Overview
 - 8.3.1.3. Financial (Subject to Data Availability)
 - 8.3.1.4. Product Summary
 - 8.3.1.5. Market Strategies
 - 8.3.2. F. Hoffmann-La Roche Ltd.
 - 8.3.3. Novartis AG
 - 8.3.4. GlaxoSmithKline plc
 - 8.3.5. Pfizer Inc.
 - 8.3.6. AbbVie Inc.
 - 8.3.7. CSL Behring
 - 8.3.8. Grifols, S.A.
 - 8.3.9. argenx SE
 - 8.3.10. Bausch Health Companies Inc.
 - 8.3.11. Catalyst Pharmaceuticals
 - 8.3.12. Takeda Pharmaceutical Company Limited
 - 8.3.13. Immunovant, Inc.
 - 8.3.14. CuraTeQ Biologics
 - 8.3.15. UCB S.A.

CHAPTER 9. RESEARCH PROCESS

9.1. Research Process

9.1.1. Data Mining

9.1.2. Analysis

9.1.3. Market Estimation

9.1.4. Validation

9.1.5. Publishing

9.2. Research Attributes

I would like to order

Product name: Global Myasthenia Gravis Treatment Market Size study, by Treatment Type (Thymectomy, Cholinesterase Inhibitors, Rapid Immunotherapies), by End-use (Hospitals, Clinics), and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G68168029DA5EN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G68168029DA5EN.html>